Mendelian susceptibility to mycobacterial diseases due to complete RORgamma receptor deficiency Advocacy Hub | UniteRare

At a Glance

Live from database

Regulatory Watchboard

No FDA or trial events recorded yet for Mendelian susceptibility to mycobacterial diseases due to complete RORgamma receptor deficiency.

Financial Assistance

1 program

FINANCIAL LANDSCAPE SUMMARY

Total programs

Open now

Patient Assistance Programs1

Trogarzo

Theratechnologies Inc.

OpenContact for details

View all support programs on disease page →

Approved Treatments

1 FDA-approved

Trogarzo

(ibalizumab)Orphan drugstandard

Theratechnologies Inc.

CD4-directed Blocking Antibody [EPC]

12.1 Mechanism of Action Ibalizumab-uiyk is an HIV-1 antiretroviral drug [see Microbiology ( 12.4 )] .

FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

No active clinical trials currently recruiting for Mendelian susceptibility to mycobacterial diseases due to complete RORgamma receptor deficiency.
Search all trials →

Search clinical trials for Mendelian susceptibility to mycobacterial diseases due to complete RORgamma receptor deficiency →

Recent News & Research

No recent news articles indexed yet for Mendelian susceptibility to mycobacterial diseases due to complete RORgamma receptor deficiency.
Search PubMed for Mendelian susceptibility to mycobacterial diseases due to complete RORgamma receptor deficiency →

Browse all Mendelian susceptibility to mycobacterial diseases due to complete RORgamma receptor deficiency news →

Specialist Network

No specialists currently listed for Mendelian susceptibility to mycobacterial diseases due to complete RORgamma receptor deficiency.

View all Mendelian susceptibility to mycobacterial diseases due to complete RORgamma receptor deficiency specialists →

Quick Actions

📄

View Disease Page

Full profile, treatments, community

🔬

Search Clinical Trials

Find recruiting studies now

🩺

Find Specialists

Ranked by expertise & trials

💰

Financial Assistance

Copay cards, PAPs, grants

📰